Pharmaceutical

ND-10 ER by Theialife Sciences for Myopia: Likelihood of Approval

ND-10 ER is under clinical development by Theialife Sciences and currently in Phase II for Myopia.

Dec 20, 2023 - 18:00
ND-10 ER is under clinical development by Theialife Sciences and currently in Phase II for Myopia.
Read the original article

Tags:

Previous Article

FLU-SV-mRNA by Curevac for Influenza A Virus, H1N1 Subtype Infections: Likelihoo...

Next Article

MABS-139 by Manhattan Biosolutions for Solid Tumor: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA warns of rare hypersensitivity reaction due to antiseizure drugs

FDA warns of rare hypersensitivity reaction due to anti...

Dec 30, 2023

BMS bags UK advanced melanoma win for Opdualag

BMS bags UK advanced melanoma win for Opdualag

Dec 28, 2023

Risk adjusted net present value: What is the current va...

Nov 18, 2023